bayesian dose response analysis for concave linear and
play

Bayesian Dose Response Analysis for Concave, Linear, and Convex - PowerPoint PPT Presentation

Bayesian Dose Response Analysis for Concave, Linear, and Convex Monotone DR Curves Michel Friesenhahn and Paul Manser May 12, 2017 Confidential do not copy, distribute or use without prior written consent. Introduction 2 Who are we?


  1. Bayesian Dose Response Analysis for Concave, Linear, and Convex Monotone DR Curves Michel Friesenhahn and Paul Manser May 12, 2017 Confidential — do not copy, distribute or use without prior written consent.

  2. Introduction 2  Who are we? – Work at Genentech/Roche supporting early development non oncology – CNS (e.g. Alzheimer’s Disease, ALS, Pain) – Ophthalmology  Why do we worry about dose-response characterization? – Safety and tolerability – Manufacturing (particularly for certain large molecules) – Minimize patient burden (e.g. frequency of dosing in ophthalmology)  We believe there are advantages to expressing uncertainty with Bayesian methods. This can aid informed dose selection, but … – How to select good priors, particularly when there is no prior information on shape? – Model selection? Model averaging?  Propose fitting a novel single family of concave, linear, and convex DR curves – Has very geometrically interpretable parameters to aid in setting of priors – Reduces or eliminates need for model selection/averaging Confidential — do not copy, distribute or use without prior written consent.

  3. Emax Model for Concave and Monotone DR 3 Confidential — do not copy, distribute or use without prior written consent.

  4. Re-parameterize 4 Tested Dose Range Maximum treatment effect over tested dose range is: Confidential — do not copy, distribute or use without prior written consent.

  5. Re-parameterize 5 Diagonal 1 Diagonal 2  Maximal distance from Diagonal 1 is on Diagonal 2 (Point B)  Tangent at point B is parallel to Diagonal 1 Confidential — do not copy, distribute or use without prior written consent.

  6. Lambda is Geometrically Interpretable 6  Re-parameterized Emax has directly interpretable parameters: Confidential — do not copy, distribute or use without prior written consent.

  7. Also Spans Linear and Convex DR Curves 7  Natural mapping from to Concave , Linear and Convex DR curves  We call this a Concavex DR family  Could use MLE, perhaps with one further re-paramterization: Confidential — do not copy, distribute or use without prior written consent.

  8. Setting Prior for λ 8  Theoretically-Motivated Non-informative – Jeffrey’s Prior – Bornkamp’s Prior Parameters considered as points in a metric space • Put uniform prior in the metric space to “spread out” the curves • Induces a prior on the parameters • – Approximations to Jeffrey’s and Bornkamp’s priors? Work in progress  Pragmatically-Motivated Non-informative – Uniform – Beta(1/3,1/3)  Interpretability of λ should aid in setting prior when some information is available Confidential — do not copy, distribute or use without prior written consent.

  9. Example for Trial in Knee Pain 9 Concavex Priors Confidential — do not copy, distribute or use without prior written consent.

  10. Posterior Parameter Distributions 10 θ 1 = 1.092 (0.570, 1.589) P(θ 1 > Efficacy Threshold C Some text here C) 0 points 0.999 0.5 points 0.968 0.75 points 0.864 1 point 0.617 Confidential — do not copy, distribute or use without prior written consent.

  11. Basic Dose-Response Characterization 11 Confidential — do not copy, distribute or use without prior written consent.

  12. Characterizing Efficacy Risks vs Dose 12 Target Efficacy Risks Suboptimal Efficacy Risks Ph 3 Efficacy Risks Confidential — do not copy, distribute or use without prior written consent.

  13. Standard Emax with Uniform Prior on ED 50 13 Emax Priors Concavex Priors Confidential — do not copy, distribute or use without prior written consent.

  14. Summary for Concavex Model 14  Single model family for concave, linear and convex dose response curves  Eliminates (or reduces) need for model selection or model averaging  Could be fit using maximum likelihood, but would suggest one further re- parameterization of λ  We focus on efficacy risk profiles as a meaningful input to dose selection – Most naturally obtained via Bayesian framework – Interpretability of Concave model aids in setting transparent priors  Development version of concavex R package currently available on GitHub – github.com/paulmanser/concavex Confidential — do not copy, distribute or use without prior written consent.

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend